Your browser doesn't support javascript.
loading
Dose-specific clinical outcomes in patients with opioid use disorder treated with 24-32 mg/day of buprenorphine.
D'Agata Mount, Julia; Sun, Junfeng; Davis, Ashley; Cover, Amelia; Sun, Lily; Gannon, Catherine; Derenoncourt, Meghan; Garrett, Grace; Eyasu, Rahwa; Ebah, Emade; Bijole, Phyllis; Greenblatt, Aaron; Kattakuzhy, Sarah; Rosenthal, Elana.
Afiliación
  • D'Agata Mount J; The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
  • Sun J; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
  • Davis A; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
  • Cover A; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Sun L; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Gannon C; Haverford College, Haverford, PA, USA.
  • Derenoncourt M; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
  • Garrett G; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
  • Eyasu R; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Ebah E; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
  • Bijole P; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Greenblatt A; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Kattakuzhy S; HIPS, Org, Washington, DC, USA.
  • Rosenthal E; Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Addiction ; 119(11): 1964-1972, 2024 Nov.
Article en En | MEDLINE | ID: mdl-38978176
ABSTRACT
BACKGROUND/

AIMS:

In people with opioid use disorder (OUD), buprenorphine is a vital treatment to decrease opioid use and overdose. The US Food and Drug Administration's prescribing information for buprenorphine advises dosing up to 24 mg/day; however, doses of buprenorphine up to 32 mg have been shown to be safe and effective. We compared outcomes associated increased dosing from 24 to 32 mg/day.

DESIGN:

Prospective cohort investigation.

SETTING:

Low-barrier buprenorphine clinic in Washington, District of Columbia, USA.

PARTICIPANTS:

Participants in the ANCHOR study (people with hepatitis C virus (HCV), OUD, and active opioid misuse who were treated for HCV and offered buprenorphine) who received buprenorphine at doses of 24 and/or 32 mg/day. 72 participants were included in the

analysis:

24 (33%) patients stabilized on 24 mg, and 48 (67%) patients stabilized on 32 mg. Patients were predominantly male (78%), Black (96%), unstably housed (57%), and used opioids by injection (93%). MEASUREMENTS Patient-reported drug use, use frequency, triggers for use, and urine drug screens were collected at each visit. For analysis, the cohort was divided into individuals stabilized on 24 mg (24 mg cohort) or 32 mg (32 mg cohort). Drug use outcomes were assessed between cohorts at 24 mg dosing and at respective maximum dosing. Within the 32 mg cohort, outcomes were compared at 24 mg versus 32 mg dosing.

FINDINGS:

Within the 32 mg cohort, increased dosing from 24 to 32 mg was associated with a decline in opioid use (68.5% [5.2%] at 24 mg vs 59.5% [5.6%] at 32 mg; P = 0.02), frequency of use per week (1.58 [0.19] at 24 mg vs. 1.15 [0.16] at 32 mg; P = 0.0002) and physiologic triggers for use (38.2% [6.0%] at 24 mg vs 7.0% [1.9%] at 32 mg; P < 0.0001). At the end of the study period, there were significantly more patients retained in the 32 mg cohort (78.7%) compared with the 24 mg cohort (50.0%, P = 0.02).

CONCLUSION:

Higher buprenorphine dosing (32 mg/day) appears to improve outcomes in people with opioid use disorder, even in the absence of abstinence.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Buprenorfina / Relación Dosis-Respuesta a Droga / Tratamiento de Sustitución de Opiáceos / Trastornos Relacionados con Opioides Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Addiction Asunto de la revista: TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Buprenorfina / Relación Dosis-Respuesta a Droga / Tratamiento de Sustitución de Opiáceos / Trastornos Relacionados con Opioides Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Addiction Asunto de la revista: TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido